Salute e Benessere
Servier's Vorasidenib Receives Approval as Clinical Urgently Needed Drug to be Used in Boao Lecheng Pilot Zone
Gliomas represent the most common primary malignant brain tumors and the most common tumors of the central nervous system. Currently, treatment options for glioma are very limited. Even with a multi-modal approach combining surgical resection, concurrent chemoradiation and adjuvant chemotherapy, over 90% of glioma patients experience recurrence and disease progression.
IDH mutation has been identified as an important oncogene for glioma and plays a pivotal role in its occurrence and development. As the world's first dual inhibitor of IDH1 and IDH2, Vorasidenib can offer significant benefits to patients compared with current treatments, particularly for those with IDH1 and IDH2 mutations.
stated, "Servier, as an independent group governed by a non-profit foundation, has always prioritized addressing patients' medical needs and we are committed to work together with healthcare professionals to improve patients' treatment outcomes and quality of life. This commitment drives our investment in research and the development of innovative therapies. The success of Voranigo's launch in Bo'ao is rooted in the belief that every patient should have access to the best treatments available, and we are committed to making that a reality here in
China ."
Meanwhile, a real-world study is underway simultaneously in Boao Lecheng to assess the safety and efficacy of Vorasidenib in the Chinese patients. It can accelerate the research process, often delivering results 1-2 years faster than traditional clinical trials.
View original content: https://www.prnewswire.co.uk/news-releases/serviers-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in-boao-lecheng-pilot-zone-302314841.html